Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.0
4.5
Journals
Cancers
Special Issues
Endometrial Cancer—Diagnosis and Treatment
share announcement

Endometrial Cancer—Diagnosis and Treatment

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: 15 December 2025 | Viewed by 1579

Special Issue Editors

Prof. Dr. Alberto Izzotti

E-Mail Website
Guest Editor
Department of Experimental Medicine (DIMES), University of Genoa, Genoa, Italy
Interests: microRNA; epigenetic modulation; cancer; oxidative stress; biomarker; endometrial cancer
Special Issues, Collections and Topics in MDPI journals
Dr. Fabio Barra

E-Mail Website
Guest Editor
Unit of Obstetrics and Gynecology, P.O. "Ospedale del Tigullio"-ASL4, via Gio Batta Ghio 9, Chiavari, 16043 Genoa, Italy
Interests: endometrial cancer; ultrasound; gynecology; laparoscopy; minimally invasive surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Endometrial cancer is the most common gynecologic malignancy, with an increasing incidence, particularly in postmenopausal women. Advances in this disease's diagnostic and surgical management are crucial to improving outcomes while minimizing the impact on patients’ quality of life. This Special Issue on “Endometrial Cancer—Diagnosis and Treatment” focuses on the gynecological aspects of managing the disease, particularly early-stage diagnosis and innovative surgical techniques. Integrating the new molecular classification of endometrial cancer, which categorizes tumors based on genetic alterations, significantly improves tailoring treatment strategies and predicting prognosis.

A key focus will be sentinel lymph node mapping, which has become essential in accurately staging early-stage disease and minimizing lymphadenectomy-related complications. Additionally, this issue will address the importance of identifying hereditary genetic syndromes, such as Lynch syndrome, which predispose women to developing endometrial cancer at an early age. Contributions related to the latest diagnostic tools, including advanced imaging, molecular markers, and minimally invasive surgical techniques, are encouraged. This issue aims to provide a comprehensive, gynecologically focused approach to the management of endometrial cancer, with an emphasis on early detection and personalized care.

Prof. Dr. Alberto Izzotti
Dr. Fabio Barra
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • endometrial cancer
  • Lynch syndrome
  • oncology
  • sentinel lymph node
  • uterine cancer
  • molecular classification

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

18 pages, 2517 KiB  
Article
The Application of Liquid Biopsy for the Development and Validation of a Non-Invasive Screening and Diagnosis Test for Endometrial Premalignant and Malignant Lesions: A Prospective Innovative Pilot Study
by Giuseppina Esposito, Giuseppe D’Angelo, Luigia De Falco, Eloisa Evangelista, Giovanni Savarese, Antonio Fico, Federica Cinque, Pierluigi Giampaolino, Attilio Di Spiezio Sardo, Giuseppe Bifulco and Luigi Della Corte
Cancers 2025, 17(7), 1078; https://doi.org/10.3390/cancers17071078 - 23 Mar 2025
Viewed by 517
Abstract
Background/Objectives: Endometrial cancer (EC) is a common malignancy in developed countries, with incidence closely linked to lifestyle factors and genetic predispositions, notably Lynch syndrome. Traditional biopsy methods for diagnosis and monitoring are invasive. This study aims to develop and validate a non-invasive [...] Read more.
Background/Objectives: Endometrial cancer (EC) is a common malignancy in developed countries, with incidence closely linked to lifestyle factors and genetic predispositions, notably Lynch syndrome. Traditional biopsy methods for diagnosis and monitoring are invasive. This study aims to develop and validate a non-invasive diagnostic method for EC using liquid biopsy, specifically examining circulating tumor DNA (ctDNA) for its potential in early detection and disease monitoring. Methods: A cohort of 63 patients with EC or atypical endometrial hyperplasia (AEH) was recruited from the Gynecological Unit of the Azienda Ospedaliera Universitaria Federico II. Plasma samples were processed to extract ctDNA, which was sequenced and analyzed for mutations. Matched tumor tissue and germline DNA were also examined to confirm mutation concordance and assess potential genetic predispositions. Results: Pathogenic mutations were identified in plasma ctDNA in 59 out of 63 cases (93%), with a 65% concordance between plasma ctDNA mutations and those found in solid tumor samples. Key mutations in genes such as PTEN, PIK3R1, and KMT2C were significantly associated with a higher tumor grade and advanced stage disease, such as myometrial infiltration. Conclusions: Liquid biopsy shows promise as a minimally invasive diagnostic and monitoring tool for EC, offering real-time insights into tumor biology. The high mutation concordance between the plasma ctDNA and tumor tissue underscores the potential of a liquid biopsy in managing EC, particularly for patients at risk of recurrence. Further longitudinal studies are needed to establish ctDNA as a standard tool in EC diagnosis and monitoring. Full article
(This article belongs to the Special Issue Endometrial Cancer—Diagnosis and Treatment)
►▼ Show Figures

Figure 1

13 pages, 646 KiB  
Article
Impact of the FIGO 2023 Staging System on the Adjuvant Treatment of Endometrial Cancer: A Comparative Analysis with FIGO 2009
by Federico Ferrari, Elisa Gozzini, Jacopo Conforti, Andrea Giannini, Fabio Barra, Anna Fichera, Filippo Alberto Ferrari, Hooman Soleymani majd and Franco Odicino
Cancers 2025, 17(6), 934; https://doi.org/10.3390/cancers17060934 - 10 Mar 2025
Viewed by 731
Abstract
Background: ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) has brought about the publication of the FIGO 2023 staging system with a significant impact in practice for endometrial cancer (EC). Methods: In this comparative study, we investigated the need for adjuvant treatment according [...] Read more.
Background: ProMisE (Proactive Molecular Risk Classifier for Endometrial Cancer) has brought about the publication of the FIGO 2023 staging system with a significant impact in practice for endometrial cancer (EC). Methods: In this comparative study, we investigated the need for adjuvant treatment according to FIGO 2023, for each FIGO 2009 stage. We prospectively enrolled EC patients from June 2021 to June 2024, collected classical risk factors and classified according to FIGO 2009. Afterwards, we reclassified the same women according to FIGO 2023 and grouped them according to ESMO/ESTRO/ESGO risk factors. Results: We collected 211 eligible patients. We found 176 patients with FIGO 2009 I–II and 35 women with FIGO 2009 III–IV. Based on classic anatomopathological risk factors and FIGO 2009, adjuvant treatment was indicated in 124 (70.5%) patients with FIGO 2009 I–II (vaginal brachytherapy = 48; external beam radiotherapy with or without vaginal brachytherapy = 63; chemotherapy with external beam radiotherapy with or without vaginal brachytherapy = 13) and in 35 (100%) women with FIGO 2009 III–IV (all underwent chemotherapy). After FIGO 2023 re-staging, the women with early-stage EC, were more frequently candidates for no treatment, with a decreased relative risk (RR) for adjuvant treatment (RR 0.84; CI95% 0.74–0.95; p < 0.01) when compared to the previous FIGO classification. No significant risk (RR 1.01; CI95% 0.76–1.3; p = 0.08) for a more aggressive adjuvant treatment was noted after FIGO 2023 re-staging. In FIGO stage III–IV, no changes in the treatment modalities were observed. Conclusions: The re-staging according to FIGO 2023 of women previously staged to FIGO 2009 I–II, yields an RR of 0.84 to spare any type of adjuvant treatment. Full article
(This article belongs to the Special Issue Endometrial Cancer—Diagnosis and Treatment)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop